← Eichor
Condition: Mycobacterium Abscessus Lung Disease Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mycobacterium Abscessus Lung Disease

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic F
Phase N/A · 1 location(s) · Ospedale San Raffaele · NCT06413459
Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure
Phase N/A · 2 location(s) · Research Center Borstel · NCT07369414
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Phase 2/Phase 3 · 50 location(s) · The University of Queensland · NCT04310930
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
Phase 1 · 10 location(s) · Chris Goss · NCT04294043
Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
Phase 2 · 1 location(s) · Kevin Winthrop · NCT07301320
The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance
Phase 4 · 1 location(s) · National Taiwan University Hospital · NCT07514364
TCM as an Adjuvant Treatment in Mycobacterium Abscessus Pulmonary Disease
Phase 2 · 8 location(s) · Shanghai University of Traditional Chinese Medicine · NCT07295938
Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease
NA · 1 location(s) · Taipei Veterans General Hospital, Taiwan · NCT07647575
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.